Apogem Capital LLC Metacrine, Inc. Transaction History

Apogem Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $56,739 - $339,552	-88,656 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $55,681 - $81,922	21,334 Added 31.69%	88,656 $304,000
Q2 2021 Aug 16, 2021	BUY	$3.37 - $5.73 $147,885 - $251,449	43,883 Added 187.22%	67,322 $256,000
Q1 2021 May 14, 2021	SELL	$6.2 - $11.0 $72,608 - $128,821	-11,711 Reduced 33.32%	23,439 $145,000
Q4 2020 Feb 16, 2021	BUY	$7.75 - $11.42 $272,412 - $401,413	35,150 New	35,150 $276,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Apogem Capital LLC with notifications on news.